Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 23.80M shares outstanding
USKalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Dr. Patel
Trustee
Mr. Sinha
Chief Executive Officer
Brett R. Hagen
Chief Accounting Officer and Principal Accounting & Financial Officer
Andrew Oxtoby
President, Chief Executive Officer & Director
Employees
20
Country
US
Sector
Healthcare
Website
kalaristx.com
Loading congressional disclosures…
based on 23.80M shares outstanding
US30d Avg
85.11K
60d Avg
68.47K
90d Avg
254.42K
